PMID- 29316343 OWN - NLM STAT- MEDLINE DCOM- 20190709 LR - 20240102 IS - 2190-6009 (Electronic) IS - 2190-5991 (Print) IS - 2190-5991 (Linking) VI - 9 IP - 2 DP - 2018 Apr TI - Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. PG - 358-368 LID - 10.1002/jcsm.12251 [doi] AB - BACKGROUND: Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease. METHODS: A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high-sensitivity multiplex was used for increased sensitivity for nine cytokines. RESULTS: Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interferon-gamma (IFN-gamma), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein-1 (MCP-1) was increased in treatment-naive cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-naive cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. CONCLUSIONS: Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment-naive patients have higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia. CI - (c) 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. FAU - Talbert, Erin E AU - Talbert EE AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH, 43210, USA. FAU - Lewis, Heather L AU - Lewis HL AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Farren, Matthew R AU - Farren MR AD - Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA. FAU - Ramsey, Mitchell L AU - Ramsey ML AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA. FAU - Chakedis, Jeffery M AU - Chakedis JM AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Rajasekera, Priyani AU - Rajasekera P AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. FAU - Haverick, Ericka AU - Haverick E AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Sarna, Angela AU - Sarna A AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Bloomston, Mark AU - Bloomston M AD - 21st Century Oncology, Inc., Fort Myers, FL, 33966, USA. FAU - Pawlik, Timothy M AU - Pawlik TM AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Zimmers, Teresa A AU - Zimmers TA AD - Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. FAU - Lesinski, Gregory B AU - Lesinski GB AD - Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA. FAU - Hart, Phil A AU - Hart PA AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA. FAU - Dillhoff, Mary E AU - Dillhoff ME AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Schmidt, Carl R AU - Schmidt CR AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, OH, 43210, USA. FAU - Guttridge, Denis C AU - Guttridge DC AD - Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program, The Ohio State University, Columbus, OH, 43210, USA. AD - Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH, 43210, USA. LA - eng GR - R01 CA180057/CA/NCI NIH HHS/United States GR - R01 CA194593/CA/NCI NIH HHS/United States GR - R01 CA122596/CA/NCI NIH HHS/United States GR - T32 CA106196/CA/NCI NIH HHS/United States GR - T32 CA090223/CA/NCI NIH HHS/United States GR - P30 CA016058/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180107 PL - Germany TA - J Cachexia Sarcopenia Muscle JT - Journal of cachexia, sarcopenia and muscle JID - 101552883 RN - 0 (Chemokine CCL2) RN - 0 (Peptide Fragments) RN - 0 (monocyte chemoattractant protein 1 (66-77)) SB - IM MH - Aged MH - Cachexia/*genetics/pathology MH - Chemokine CCL2/*adverse effects/*genetics MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pancreatic Neoplasms MH - Peptide Fragments/*adverse effects/*genetics PMC - PMC5879958 OTO - NOTNLM OT - Biomarker OT - Wasting OT - Weight loss EDAT- 2018/01/10 06:00 MHDA- 2019/07/10 06:00 PMCR- 2018/04/01 CRDT- 2018/01/10 06:00 PHST- 2017/05/12 00:00 [received] PHST- 2017/07/27 00:00 [revised] PHST- 2017/09/05 00:00 [accepted] PHST- 2018/01/10 06:00 [pubmed] PHST- 2019/07/10 06:00 [medline] PHST- 2018/01/10 06:00 [entrez] PHST- 2018/04/01 00:00 [pmc-release] AID - JCSM12251 [pii] AID - 10.1002/jcsm.12251 [doi] PST - ppublish SO - J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):358-368. doi: 10.1002/jcsm.12251. Epub 2018 Jan 7.